REPONEX PHARMACEUTICALS A/S: Financial statements 2013
CVR: 30082346
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2013. In 2013, the company reported a net result of DKK 149,866 compared with DKK -17,837 the year before. Equity in the 2013 report amounted to DKK 229,616. The solvency ratio was 11.5%.
- Profit/Loss
- DKK 149,866
- Equity
- DKK 229,616
- Total Assets
- DKK 2,001,644
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
REPONEX PHARMACEUTICALS A/S has published its annual report for 2012. The net result was DKK -17,837.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.